Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Lifestyle change remains the foundation for all weight loss GLP-1 agonists like Wegovy and Saxenda are designed to be used for the chronic treatment of obesity, not something to be used in the short-term
Today, for the first time in a decade: 1) Domestic branded is growing double-digit with chronic shift accelerating and GLP-1 creating new TAM 2) US formulations have graduated from commodity to complexity, with biosimilars opening a new profit pool 3) ROW markets are scaling with EU GMP and branded strategies 4) CDMO is riding the strongest tailwind in its history (China+1 + patent cliffs + new modalities) 5) API pricing is stabilizing after three years of deflation 6) Innovation pipelines are producing real clinical and commercial milestones 7) Capital allocation is disciplined and shareholder-friendly But What Could Derail the Story
BPC 157 is used as a drug, food or dietary supplement
PMID 12032748
US$ 20.54
US$ 23.40
US$ 23.37
